fezakinumab
mAbexperimental
Fezakinumab is a human monoclonal antibody against interleukin-22, designed for the treatment of psoriasis and rheumatoid arthritis. — Wikipedia
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00447681)
Timeline
Indications
Mechanism of action
- Interleukin-22INHIBITOR
IL22 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFezakinumab ↗
- ChEMBLCHEMBL1743017 ↗
Also known as
- fezakinumab
- fezakinumab
- ilv-094
- ilv-094
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01941537 | Phase 2 | Oct 1, 2013 | Icahn School of Medicine at Mount Sinai, Rockefeller University |
| NCT00883896 | Phase 2 | Jun 1, 2009 | Pfizer |
| NCT00563524 | Phase 1 | Dec 1, 2007 | Pfizer |
| NCT00434746 | Phase 1 | Jan 1, 2007 | Pfizer, Wyeth |
| NCT00447681 | Phase 1 | Dec 1, 2006 | Pfizer, Wyeth |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 2 | 2006 |
| Wyeth | For profit | 2 | 0 | 1 | 2006 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Rockefeller University | Academic/Hospital | 1 | 1 | 1 | 2013 |
4 organizations
Page 1 / 1